Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will likely be releasing its Status update results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($2.39) per share for the quarter. Investors are encouraged to explore the company’s upcoming Status update earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:30 AM ET.

Seres Therapeutics Trading Up 3.8%

Shares of NASDAQ MCRB opened at $9.13 on Thursday. The business has a 50-day moving average of $13.15 and a 200-day moving average of $16.23. The firm has a market capitalization of $82.63 million, a price-to-earnings ratio of -2.56 and a beta of 0.31. Seres Therapeutics has a 12 month low of $6.53 and a 12 month high of $29.98.

Hedge Funds Weigh In On Seres Therapeutics

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in Seres Therapeutics by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after purchasing an additional 1,160 shares in the last quarter. Invesco Ltd. grew its position in shares of Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after buying an additional 3,918 shares during the period. State Street Corp increased its stake in shares of Seres Therapeutics by 14.0% in the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 4,170 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 4.8% during the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after acquiring an additional 4,723 shares during the period. Finally, Bank of America Corp DE boosted its stake in Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 5,157 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on MCRB. Wall Street Zen lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “sell (d)” rating on shares of Seres Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Seres Therapeutics has an average rating of “Reduce” and an average price target of $14.33.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.